AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...
Achieving International Drug Price Parity: Trump’s Mandate
President Donald J. Trump’s July 31, 2025 fact sheet outlines a sweeping policy initiative to enforce international drug price parity. It aims to compel pharmaceutical companies to lower U.S. prescription drug prices to match the lowest prices offered in other developed nations. This policy intro...
NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long...
Enhancing Patient Involvement in EU JCAs
Patient involvement in EU Joint Clinical Assessments (JCAs) is crucial for ensuring healthcare policies reflect patient needs. The article, "Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments," by Anne-Pierre Pickaert, compares patient involvement stra...
NICE HealthTech Methods Update

By João L. Carapinha

August 5, 2025

The latest consultation draft of the NICE HealthTech Methods Update outlines methodological revisions for developing health technology (HealthTech) guidance. It emphasizes processes for early and existing use assessments within the NHS. Central to the update are enhanced framewor...
Navigating AI Act Implementation Challenges in MedTech
MedTech Europe recently marked the first anniversary of the EU Artificial Intelligence Act (AI Act). It highlights challenges in implementing the AI Act, such as regulatory overlap with the Medical Devices Regulation (MDR)/IVDR frameworks. This overlap could delay patient access to innovative med...
Search By Category

Latest

AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...

Latest

Achieving International Drug Price Parity: Trump’s Mandate
President Donald J. Trump’s July 31, 2025 fact sheet outlines a sweeping policy initiative to enforce international drug price parity. It aims to compel pharmaceutical companies to lower U.S. prescription drug prices to match the lowest prices offered in other developed nations. This policy intro...

Latest

NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long...

Latest

Enhancing Patient Involvement in EU JCAs
Patient involvement in EU Joint Clinical Assessments (JCAs) is crucial for ensuring healthcare policies reflect patient needs. The article, "Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments," by Anne-Pierre Pickaert, compares patient involvement stra...

Global Updates

AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...

Global Updates

Achieving International Drug Price Parity: Trump’s Mandate
President Donald J. Trump’s July 31, 2025 fact sheet outlines a sweeping policy initiative to enforce international drug price parity. It aims to compel pharmaceutical companies to lower U.S. prescription drug prices to match the lowest prices offered in other developed nations. This policy intro...

Global Updates

NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long...

Global Updates

Enhancing Patient Involvement in EU JCAs
Patient involvement in EU Joint Clinical Assessments (JCAs) is crucial for ensuring healthcare policies reflect patient needs. The article, "Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments," by Anne-Pierre Pickaert, compares patient involvement stra...

Europe

AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured ...
NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long...
Enhancing Patient Involvement in EU JCAs
Patient involvement in EU Joint Clinical Assessments (JCAs) is crucial for ensuring healthcare policies reflect patient needs. The article, "Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments," by Anne-Pierre Pickaert, compares patient involvement stra...
NICE HealthTech Methods Update

By João L. Carapinha

August 5, 2025

The latest consultation draft of the NICE HealthTech Methods Update outlines methodological revisions for developing health technology (HealthTech) guidance. It emphasizes processes for early and existing use assessments within the NHS. Central to the update are enhanced framewor...

Middle East

Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author sh...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China

By João L. Carapinha

May 14, 2025

The economic ramifications of hepatitis C (HCV) are staggering. Estimates suggest the disease could impose a $1.17 trillion burden on China from 2023 to 2050. This is the crux of the hepatitis C investment impact article we cover below, meeting WHO's 2030 HCV diagnosis and treatment targets requi...
Implementing Health Technology Assessment in Oman

By João L. Carapinha

May 6, 2025

A recent article titled "A roadmap towards implementing health technology assessment in Oman" outlines a strategy for integrating health technology assessment in Oman into the healthcare system over the next decade. This initiative aims to improve resource allocation and facilita...
AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

By João L. Carapinha

April 22, 2025

A recent peer-reviewed study examined the effectiveness of AI patient education by comparing ChatGPT and Gemini in generating educational materials for common pediatric exanthematous conditions, including varicella, hand, foot, and mouth disease (HFMD), and measles. The findings indicated that Ch...

Sub-Saharan Africa

Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....
ARVs Water Impact: Examining the Environmental Consequences of Antiretroviral Drugs in South Afri...

By João L. Carapinha

July 29, 2025

A study by North-West University found high levels of HIV antiretrovirals (ARVs) in South African water systems. The ARVs lopinavir and efavirenz were detected downstream of wastewater plants, exceeding safety limits. These pose risks to aquatic life, such as altered snail development and disrupt...
Lenacapavir HIV Prevention: Gilead’s Strategic Agreement to Enhance Access in Low-Income Co...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly injectable for pre-exposure prophylaxis (PrEP) against H...